Documentation of drug interchange in the medical record.

Hosp Pharm

Charlton Memorial Hospital, Fall River, MA 02720.

Published: January 1991

The hospital medical record has become increasingly exposed to retrospective audits by third party insurers, quality assessment studies, and billing inquiries. As a result, the demand for complete documentation in the record has steadily increased during the past few years. Institutional medical practices are subject to a variety of regulations and standards. Economic pressures are continually exerted on hospitals for cost reduction measures, which include patient drug costs. While hospitals have engaged in a variety of methods of drug interchange to reduce costs, documentation procedures for interchange are not specifically regulated. The Joint Commission on Accreditation of Healthcare Organizations (JCAHO) appears to be the only source for applicable regulations regarding medical record documentation. With respect to therapeutic drug interchange, few guidelines exist to "legalize" this common practice. A procedure to provide the physician's informed consent for therapeutic interchange is explained. This article will focus on drug interchange notification procedures for non-teaching community hospitals. Legalities, practicalities, and regulations for medical record documentation are addressed. In addition, suggestions for the documentation of drug interchange are proposed.

Download full-text PDF

Source

Publication Analysis

Top Keywords

drug interchange
20
medical record
16
documentation drug
8
regulations medical
8
record documentation
8
interchange
7
documentation
6
medical
5
record
5
drug
5

Similar Publications

Background: Reporting serious adverse events (SAEs) is crucial to reduce or avoid toxicities that can lead to major consequences for patient's health due to treatments tested in clinical trials. Its exhaustiveness is often inadequate, and we observe discrepancies between data published by pharmacovigilance organizations and clinical databases.

Objectives: While the process of reconciliation aims at reducing these differences, it remains a very time-consuming and imprecise task.

View Article and Find Full Text PDF

Dried blood spot (DBS) assays to quantify novel and repurposed drugs for the treatment of rifampicin-resistant tuberculosis (RR-TB) would facilitate pharmacokinetic studies and therapeutic drug monitoring in low-middle income settings, considering their ease of application and simple sample storage requirements. We describe a DBS method for the simultaneous quantification of bedaquiline and metabolite N-desmethyl bedaquiline, linezolid, levofloxacin, and clofazimine. The analytes were extracted from the matrix and isolated by solid-phase extraction.

View Article and Find Full Text PDF

Over recent years, the LUMinescent AntiBody Sensor (LUMABS) system, utilizing bioluminescence resonance energy transfer (BRET), has emerged as a highly effective method for antibody detection. This system incorporates NanoLuc (Nluc) as the donor and fluorescent protein (FP) as the acceptor. However, the limited Stokes shift of FP poses a challenge, as it leads to significant spectral cross-talk between the excitation and emission spectra.

View Article and Find Full Text PDF

Genetically Encoded Biosensors for Constrained Biological Functions in Probiotic Nissle.

ACS Synth Biol

January 2025

State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Faculty of Medicine and Life Sciences, Xiamen University, Fujian 361102, China.

The probiotic Nissle (EcN) is an exceptional strain that has attracted significant attention not only for its clinical efficacy in the treatment and prevention of gastrointestinal disorders but also as a burgeoning microbial chassis for living therapeutic applications. However, there is an immediate necessity to develop conditional expression systems that confine the activity of EcN specifically in the gastrointestinal tract, to avoid influencing the environment. Here, we constructed two genetically encoded interchangeable sensors responsive to body temperature at 37 °C, and small molecules such as protocatechuic acid (PCA), a metabolite found in green tea.

View Article and Find Full Text PDF

Human primary (hpBMEC) and induced pluripotent stem cell (iPSC)-derived brain microvascular endothelial-like cells (hiBMEC) are interchangeably used in blood-brain barrier models to study neurological diseases and drug delivery. Both hpBMEC and hiBMEC use glutamine as a source of carbon and nitrogen to produce metabolites and build proteins essential to cell function and communication. We used metabolomic, transcriptomic, and computational methods to examine how hpBMEC and hiBMEC metabolize glutamine, which may impact their utility in modeling the blood-brain barrier.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!